Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

A superenhancer at the retinoic acid receptor alpha (RARA) gene is associated with RARA mRNA overexpression in ∼30% of non-acute promyelocytic leukemia acute myeloid leukemia (AML) and in ∼50% of myelodysplastic syndromes (MDS). RARA overexpression is an actionable target for treatment with tamibaro...

Descripción completa

Detalles Bibliográficos
Autores principales: de Botton, Stéphane, Cluzeau, Thomas, Vigil, Carlos, Cook, Rachel J., Rousselot, Philippe, Rizzieri, David A., Liesveld, Jane L., Fenaux, Pierre, Braun, Thorsten, Banos, Anne, Jurcic, Joseph G., Sekeres, Mikkael A., Savona, Michael R., Roboz, Gail J., Bixby, Dale, Madigan, Kate, Volkert, Angela, Stephens, Kristin, Kang-Fortner, Qing, Baker, Kristen, Paul, Sofia, McKeown, Michael, Carulli, John, Eaton, Matthew, Hodgson, Graeme, Fiore, Christopher, Kelly, Michael J., Roth, David A., Stein, Eytan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165187/
https://www.ncbi.nlm.nih.gov/pubmed/36477975
http://dx.doi.org/10.1182/bloodadvances.2022008806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165187/
https://www.ncbi.nlm.nih.gov/pubmed/36477975
http://dx.doi.org/10.1182/bloodadvances.2022008806

Ejemplares similares